- About Us
- Nano-Social Network
- Nano Consulting
- My Account
BioForce Nanosciences, Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc.
(OTC Bulletin Board: BFNH), continues their effort to fund development of
the ViriChip(TM) platform, a patented system designed to rapidly and
nondestructively detect and identify whole viruses. Developed by BioForce
and made possible by BioForce's Nano eNabler(TM) molecular printer, the
ViriChip platform can have a major impact in biodefense by creating
ultraminiaturized biodetection devices.
BioForce Nanosciences has three major product focus areas: 1)
instrumentation, 2) consumables, and 3) applications. The ViriChip platform
is just one application that BioForce's R&D department has developed using
the Nano eNabler system. The ViriChip technology is sensitive and specific
enough to detect a variety of different pathogens based on the availability
of capture reagents. These could include environmental pathogens
(Noroviruses, coxsackieviruses, etc.), pathogens relevant to biodefense
(smallpox, hemorrhagic fever viruses), animal and plant viruses (foot and
mouth disease, rinderpest, Avian influenza, West Nile), and human disease
agents (Human papillomavirus, herpes viruses, SARS).
BioForce Nanosciences is working to gain government and other support
for the ViriChip platform to assist with biodefense, food safety, and
pandemic diseases. "We want to create opportunities to inform scientific
leaders and decision makers about the importance of nanotechnology in the
life sciences," says Dr. Eric Henderson, BioForce's founder and chief
executive officer. "We believe that the technology embodied in our recently
released Nano eNabler(TM) system has the potential to impact nanotechnology
in the life sciences in a profound way."
About BioForce Nanosciences, Inc.
BioForce Nanosciences, Inc. is a wholly owned subsidiary of BioForce
Nanosciences Holdings, Inc. (OTC Bulletin Board: BFNH). BioForce
Nanosciences is a unique company entering into commercialization with over
a decade of research and accomplishment in the field of bionanotechnology.
BioForce has demonstrated the ability to take a product from concept to
commercial sale. For more information, visit http://www.bioforcenano.com .
This news release contains forward-looking information that may be
affected by certain risks and uncertainties, including those risks and
uncertainties described in the Company's most recent filings with the
Securities and Exchange Commission. The Company's actual results could
differ materially from such forward-looking statements. We assume no duty
to update these statements at any future date.
For more information, please click here
BioForce Nanosciences, Inc.
1615 Golden Aspen Drive, Suite 101
Ames, IA 50010 USA
Phone: 515.233.8333 ext. 101
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Notre Dame researchers find transition point in semiconductor nanomaterials September 6th, 2016
Down to the wire: ONR researchers and new bacteria August 18th, 2016